Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer death in the United States. Sorafenib, an oral tyrosine kinase inhibitor targeted against molecular signaling pathways including RAS and VEGFR, is the only systemic drug to date which has been shown to improve survival in advanced HCC. Biomarkers have not been well-studied in HCC. The goal of this proposal is to identify peripheral predictive and prognostic biomarkers related to DNA methylation in a prospective study of 200 advanced HCC patients, all treated with sorafenib. We will study a surrogate for global hypomethylation (LINE-1), and well as methylation of several gene sites thought to be involved in HCC development and progression. In particular, methylation of a particular tumor suppressor called RASSF1A has been shown to "turn on" other components of the RAS signaling pathway in HCC. Tumor expression of p-ERK, a downstream target in the RAS pathway, seems to correlate with better response to sorafenib. We will examine whether methylation of RASSF1A in plasma and tumor tissue correlates with p-ERK expression in tumor tissue. These experiments have the potential to identify simpler and safer ways to predict HCC outcomes. Finally, because of the possibility that folate may affect gene and global methylation levels, we will examine whether folate levels in plasma and red blood cells affect relationships between methylation status and outcome. Subjects will be recruited from the faculty practices at Columbia University and Weill-Cornell Medical Centers, given an epidemiologic questionnaire, and have blood drawn prior to starting sorafenib. Bloods will be processed on site, and assays will be run in the laboratory of Dr. Regina Santella, who directs the biomarker core facility of the Herbert Irving Comprehensive Cancer Center at Columbia. Folate levels will be processed by our collaborator at Columbia, Dr. Mary Gamble. In a subset of patients from Columbia we will also evaluate pathologic sections of tumor using immunohistochemistry and methylation assays. We will collaborate with both the Cancer Center's pathology core resource, together with Dr. Helen Remotti, an experienced GI pathologist, to complete these studies. This project will explore relationships between environmental, biological, and treatment-related effects on HCC outcomes in a multidisciplinary way. We believe the results will lead to the development of novel cost-effective predictive and prognostic biomarkers for those with this increasingly deadly disease.

Public Health Relevance

This project focuses on hepatocellular carcinoma, or HCC, an understudied cancer which is becoming increasingly important in the United States. Predictive and prognostic biomarkers in HCC are badly needed, especially those which can be determined from peripheral blood (rather than liver biopsy). Methylation analysis is an exciting and novel way to study predictors of outcome. Finding peripheral biomarkers that predict response to novel anti-angiogenic agents would be a huge public health advance by allowing better patient selection for potentially toxic and expensive drugs. Further, understanding the relationship between folate levels and methylation profiles of particular genes may allow for future study involving modulation of these pathways via diet and other drugs which affect folate and/or methylation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23CA149084-04
Application #
8702092
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lim, Susan E
Project Start
2011-08-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
$169,975
Indirect Cost
$12,591
Name
Columbia University (N.Y.)
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Siegel, Abby B; Goyal, Abhishek; Salomao, Marcela et al. (2015) Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients. Oncology 88:57-68
Goyal, Abhishek; Terry, Mary Beth; Jin, Zhezhen et al. (2014) C-reactive protein and colorectal cancer mortality in U.S. adults. Cancer Epidemiol Biomarkers Prev 23:1609-18
Siegel, Abby B; Narayan, Rupa; Rodriguez, Rosa et al. (2014) A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther 13:46-53
Kluger, Michael D; Halazun, Karim J; Barroso, Ryan T et al. (2014) Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl 20:536-43
El-Khoueiry, A B; Rankin, C; Siegel, A B et al. (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882-7
Goyal, Abhishek; Terry, Mary Beth; Siegel, Abby B (2013) Serum antioxidant nutrients, vitamin A, and mortality in U.S. Adults. Cancer Epidemiol Biomarkers Prev 22:2202-11
Tarallo, P A; Smolowitz, J; Carriero, D et al. (2013) Prevalence of high-risk human papilloma virus among women with hepatitis C virus before liver transplantation. Transpl Infect Dis 15:400-4